Ken Griffin Argenx Se Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Argenx Se stock. As of the latest transaction made, Citadel Advisors LLC holds 28,700 shares of ARGX stock, worth $16.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28,700
Previous 33,400
14.07%
Holding current value
$16.9 Million
Previous $13.2 Million
6.14%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding ARGX
# of Institutions
382Shares Held
31.6MCall Options Held
303KPut Options Held
429K-
Price T Rowe Associates Inc Baltimore, MD5.6MShares$3.3 Billion0.29% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.51MShares$2.07 Billion2.39% of portfolio
-
Janus Henderson Group PLC London, X02.47MShares$1.45 Billion0.58% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.92MShares$1.13 Billion0.52% of portfolio
-
Capital World Investors Los Angeles, CA1.51MShares$890 Million0.11% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $32.6B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...